Reset filter
Palabras clave
Parkinsons Disease ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
    1. 7.1. Anestesiología
    1. 7.2. Dermatología
    1. 7.3. ENT
    1. 7.4. Geriatría
    1. 7.5. Ginecología / Obstetricia
    1. 7.6. Medicina Interna
      1. Hematología
      1. Enfermedades infecciosas
      1. Cardiología / Angiología
      1. Neumología
      1. Gastroenterología
      1. Nefrología
      1. Endocrinología / Enfermedades metabólicas
      1. Reumatología
    1. 7.7. Neurología
    1. 7.8. Oftalmología
    1. 7.9. Cuidados paliativos
    1. 7.10. Patología / Forense
    1. 7.11. Pediatría
    1. 7.12. Psiquiatría / Psicosomática
    1. 7.13. Radiología
    1. 7.14. Cirugía
      1. Cirugía General / Visceral
      1. Neurocirugía
      1. Cirugía plástica
      1. Cirugía Torácica
      1. Traumatología / Ortopedia
      1. Cirugía vascular
    1. 7.15. Urología
    1. 7.16. Odontología / OMS
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

276 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 - Module 3 Visit 6 Month 6

- 20/12/17 - 1 formulario, 18 itemgroups, 51 items, 1 idioma
Itemgroups: Current Dose Level, Vital signs, Concomitant Medication, Adverse Experiences, L-Dopa Rescue, Study Medication Compliance, End of visit instructions for patients continuing, End of visit instructions for patients not continuing, ERG Examintion Appointment Card, Concomitant Medication, Details on concomitant medication, Levodopa Rescue Therapy, Details on Levodopa - rescue therapy, Adverse Experiences, Details on Adverse Experiences, Investigator´s Signature, Patient Continuation / Withdrawal, Investigator´s Signature
Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Patient Continuation / Withdrawal - L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Patient Continuation / Withdrawal

- 12/10/17 - 1 formulario, 1 itemgroup, 6 items, 1 idioma
Itemgroup: Patient continuation / withdrawal
Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Concomitant Medication/Adverse Experiences

- 12/10/17 - 1 formulario, 5 itemgroups, 24 items, 1 idioma
Itemgroups: Concomitant Medication Information, Concomitant Medication, Adverse Experiences, Adverse Experience Details, Investigator´s Signature
Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

Deep Brain Stimulation Parkinson's Disease DRKS00007526 NCT02288468 DRKS00007526 - Eligibility

- 21/6/17 - 1 formulario, 2 itemgroups, 32 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
One Pass thalamIc aNd subthalamIc stimulatiON; ODM derived from: https://clinicaltrials.gov/show/NCT02288468

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Visit 3 Week 2 (optional visit)

- 12/10/17 - 1 formulario, 5 itemgroups, 8 items, 1 idioma
Itemgroups: Vital signs, Concomitant medication, Adverse Experiences, Study Medication Compliance, Patient continuation
Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Screening/Baseline Conclusion

- 12/10/17 - 1 formulario, 2 itemgroups, 5 items, 1 idioma
Itemgroups: Screening Baseline Conclusion, Investigator´s signature
Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Screening

- 26/9/17 - 1 formulario, 15 itemgroups, 61 items, 1 idioma
Itemgroups: General Information, Informed Consent, Demography, Vital signs, Date of onset of symptoms of parkinson´s disease, Modified Hoehn and Yahr Parkinsons Disease Staging, Significant medical / surgical history and physical examination, Details on Significant medical or surgical condition, Prior anti-parkinson medication, Details on prior anti-parkinson medication, Other prior medication (excluding anti-parkinson medication), Details on other prior medication (excluding anti-parkinson medication), Inclusion Criteria, Exclusion Criteria, Laboratory tests
Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

Beck Depression Inventory GSK study Dyskinesia in Parkinson's disease NCT00363727

- 8/9/17 - 1 formulario, 2 itemgroups, 4 items, 1 idioma
Itemgroups: General information, Beck Depression Inventory
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: Beck Depression Inventory.

Eligibility Parkinson's Disease NCT00026598

- 31/7/17 - 1 formulario, 2 itemgroups, 9 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00026598

Eligibility Parkinson's Disease NCT00070941

- 21/11/16 - 1 formulario, 2 itemgroups, 19 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
SAM-e for the Treatment of Depression in Patients With Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00070941

Eligibility Parkinson NCT00358189

- 30/5/17 - 1 formulario, 2 itemgroups, 13 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00358189

Eligibility Parkinson's Disease NCT00282152

- 31/5/17 - 1 formulario, 2 itemgroups, 18 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD); ODM derived from: https://clinicaltrials.gov/show/NCT00282152

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial